Thrombophilia News and Research

RSS

AI uncovers hidden molecular signals linked to thrombosis risk

Two people may be the same age and have similar family histories or risk factors, yet only one of them may develop thrombosis.

6 Jul 2026

Date vinegar lowers blood sugar and cholesterol in type 2 diabetes

This study reveals that red date vinegar intake improves blood glucose and lipid profiles in type 2 diabetes, indicating potential for metabolic risk reduction.

22 Jul 2025

Sickle cell trait increases risk of blood clots across diverse ancestries

National Institutes of Health (NIH) researchers and collaborators have found that being a carrier for sickle cell disease, known as having sickle cell trait, increases the risk of blood clots, a risk that is the same among diverse human populations that may not traditionally be associated with sickle cell disease.

12 Sep 2024

Migraines and other nontraditional factors linked to higher stroke risk in young adults

Adults younger than 35- to 45-years old may have a higher risk of developing a stroke from nontraditional risk factors such as migraines than from traditional risks like high blood pressure.

26 Mar 2024

Study finds strong link between genetic predisposition for blood clots and contraceptive pill use

Women with a high genetic predisposition for blood clots are six times more likely to develop a blood clot during the first two years of using contraceptive pills according to a new study from Uppsala University.

19 Oct 2023

Non-alcoholic fatty liver disease linked to higher risk of blood clots in healthy adults

Recent study in Scientific Reports finds a link between nonalcoholic fatty liver disease (NAFLD) and a higher risk of venous thromboembolism (VTE) among healthy Korean adults. The research suggests that NAFLD may contribute to a hypercoagulable state, increasing the risk of VTE.

27 Sep 2023

NSAID use linked to higher risk of blood clots in women of reproductive age, association stronger in women on high-risk hormonal contraception

A new paper published in The BMJ explores the effect of these drugs used concomitantly on the risk of venous thromboembolism (VTE).

8 Sep 2023

Venous thromboembolism is rare among non-hospitalized COVID-19 patients

In a recent study published in the journal JAMA Network Open, researchers in the United States assessed the risk and aimed to identify the independent predictors of venous thromboembolism events in outpatients who had less severe manifestations of coronavirus disease 2019 (COVID-19).

16 Mar 2023

Clinical determinants of post-COVID-19 thromboembolism

Researchers quantify the risk of acute VTE due to SARS-CoV-2 infection in ambulatory settings.

27 Mar 2022

Assessing the risks of thrombotic events post vaccination with ChAdOx1 and BNT162b2 vaccines in England

Researchers aim to better understand the population-level thrombotic risks post COVID-19 vaccination with both the ChAdOx1-S and BNT162b2 vaccines.

29 Aug 2021

Investigators map how drugs were used on people hospitalized with COVID-19 infection

A record of medicine utilization patterns assembled by an interdisciplinary team of researchers at the University of California, Irvine and the UC San Diego School of Medicine reveals the thought, care and scientific rigor clinicians at UC Health medical centers applied in their treatment of patients with COVID-19 in 2020.

21 May 2021

Study highlights need to educate women and medical community about risk factors of preeclampsia

Despite its crowded healthcare market and strong efforts to make healthcare more accessible to patients, New Jersey has one of the highest maternal mortality rates in the nation - an issue so pertinent that First Lady Tammy Murphy created the Nurture NJ initiative to help reduce infant and maternal mortality.

20 Sep 2019

New clinical practice guidelines for managing venous thromboembolism released

Venous thromboembolism, a term referring to blood clots in the veins, is a highly prevalent and far-reaching public health problem that can cause disability and death.

28 Nov 2018

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial presented today in a Hot Line Session at ESC Congress 2018 and published in The New England Journal of Medicine.

27 Aug 2018

Abbott introduces Sekisui CP3000 fully automated coagulation system for accurate test results

Today, Abbott announced that the Sekisui CP3000 coagulation system, a fully automated analyzer that tests bleeding and clotting function in blood, is now available in Europe, the Middle East, and Asia Pacific.

23 Jun 2017

Opportunities and risks of direct-to-consumer genetic health risk tests

Accurate genetic testing stands to transform modern medicine by offering effective, personalized treatment.

13 Apr 2017

FDA authorizes marketing of first direct-to-consumer GHR tests for certain diseases

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions.

6 Apr 2017

Study provides more insight into treatment options for severe hemophilia A

Families of children with severe hemophilia A may want to take a fresh look at treatment options from human plasma. A study published in the New England Journal of Medicine on May 26 showed that participants who received a recombinant therapy— the present standard in the United States — developed antibodies or "inhibitors" to the treatments at almost twice the rate as those whose treatments were made from human plasma.

14 Jun 2016

New national database could help identify major influences on miscarriage

A new national database could help relieve the misery of miscarriage for thousands of women.

26 Apr 2016

Invitae announces dramatic expansion of genetic testing menu

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin releasing the new content between now and the end of the year. Invitae is immediately expanding its menu with dozens of new test panels for hereditary cancer, cardiovascular, neuromuscular, pediatric and other rare disorders.

7 Oct 2015